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Background: Despite the potential of improving the delivery of epigenetic drugs, the subsequent assessment of
changes in their epigenetic activity is largely dependent on the availability of a suitable and rapid screening
bioassay. Here, we describe a cell-based assay system for screening gene reactivation.
Methods: A cell-based assay system (EPISSAY) was designed based on a silenced triple-mutated bacterial
nitroreductase TMnfsB fused with Red-Fluorescent Protein (RFP) expressed in the non-malignant human breast cell
line MCF10A. EPISSAY was validated using the target gene TXNIP, which has previously been shown to respond to
epigenetic drugs. The potency of a epigenetic drug model, decitabine, formulated with PEGylated liposomes was
also validated using this assay system.
Results: Following treatment with DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors such
as decitabine and vorinostat, increases in RFP expression were observed, indicating expression of RFP-TMnfsB. The
EPISSAY system was then used to test the potency of decitabine, before and after PEGylated liposomal
encapsulation. We observed a 50% higher potency of decitabine when encapsulated in PEGylated liposomes, which
is likely to be due to its protection from rapid degradation.
Conclusions: The EPISSAY bioassay system provides a novel and rapid system to compare the efficiencies of
existing and newly formulated drugs that reactivate gene expression.
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DNA methylation and histone modification are the two
major epigenetic mechanisms catalyzed by DNMTs and
HDACs, respectively [1]. HDACs remove the acetyl
groups from histones, whilst DNMTs catalyse the trans-
fer of a methyl group from S-adenosylmethionine to the
5-carbon position of the cytosine pyrimidine ring, both
leading to the condensation of chromatin to its inactive
state [2,3]. In cancer cells, an abundance of hypo-
acetylated histones is usually associated with DNA
hyper-methylation and gene silencing [4]. These findings
are the basis for the development of HDAC and DNMT* Correspondence: sue.lim@adelaide.edu.au
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reproduction in any medium, provided the orinhibitors as cancer therapeutics. Such compounds block
the activity of HDACs and DNMTs, leading to increased
expression of epigenetically silenced genes which mediate
cellular and metabolic changes such as cell growth arrest,
differentiation and apoptosis [5-9].
Hydrophobic vorinostat (suberoylanilide hydroxamic acid,
SAHA) and hydrophilic decitabine (5-aza-20-deoxycytidine,
Dacogen) are US Food and Drug Administration (FDA)
approved HDAC and DNMT inhibitors for the treatment
of cutaneous T-cell lymphoma and myelodysplastic syn-
drome, respectively [10,11]. The combination of vorinostat
and decitabine have been shown to have promising activity
in patients with myelodysplastic syndrome without signifi-
cant toxicity in a phase I clinical trial [12]. Under neutral
conditions, decitabine has a reported half-life of 7 days at
4°C or 21 hours at 37°C in vitro [13]. However, decitabine is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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25 minutes [13]. Such chemical instability of decitabine
has led to its administration in the clinic as a cold and
continuous intravenous infusion in an effort to reach
the maximal-tolerated doses required to achieve clinical
response [14,15].
The development of drug formulation using nanotech-
nology (e.g. liposomes) has been used to improve drug
stability [16,17]. Despite the potential of improving the
delivery of epigenetic drugs, the subsequent assessment of
changes in their epigenetic activity is largely dependent on
the availability of a suitable and rapid screening bioassay.
A commonly used cell-based assay for both DNMT and
HDAC inhibitors is the quantification of the re-expression
of known epigenetically-silenced genes by reverse transcrip-
tion polymerase chain reaction (RT-PCR) and western blot
analysis [5,18]. However, this traditional approach is not
high-throughput and may produce gene-specific results.
Other assays that have been used include estimation of glo-
bal DNA methylation using capillary electrophoresis, DNA
digestion with methylation-sensitive restriction enzymes, or
analysis of specific DNA methylation using bisulfite sequen-
cing and methylation-specific PCR [19]. However, these
assay systems designated for assaying DNMT or HDAC in-
hibitors are time-consuming, cumbersome and subject to
misinterpretation [20-22]. Consequently, the rapid identifi-
cation and validation of novel epigenetic drugs are ham-
pered due to the lack of an efficient screening method.
In this study, a cell-based assay system was developed
to compare the activity of different epigenetic drugs.
This assay system is based on mammalian MCF10A cells
expressing a fusion protein between red-fluorescent
protein (RFP) and bacterial nitroreductase (TMnfsB)
driven by CMV promoter. Epigenetic silencing has been
shown to silence genes driven by CMV promoter in
both stably transfected cells and transgenic pigs
[23,24]. Silenced CMV promoter driven genes were
shown to be reactivated after treatment with epigenetic
drugs such as butyrate, trichostatin A and decitabine
[23]. Human cells expressing TMnfsB are able to
metabolize the monofunctional alkylating prodrug
CB1954 (5-(azaridin-1-yl)-2,4-dinitro-benzamide) to
highly cytotoxic hydroxylamino- and amino-derivatives,
which induce rapid cell death [25]. Therefore, TMnfsB
was utilized as a tool to obtain clones with inactivated
CMV promoters. The TMnfsB open reading frame has
been codon optimized to increase the sensitivity of stable
human cell lines to the prodrug CB1954 [26]. An assay
system for gene reactivation was developed by identifying
clones where expression of RFP-TMnfsB was suppressed
at the transcriptional level, but could be re-established by
subsequent treatment with epigenetic drugs. Since RFP
expression in these clones is low, it was used as a signal to
evaluate the reactivation of gene expression by flowcytometry. Using this newly developed assay system, it
was shown that decitabine which encapsulated in the
liposomes has a higher gene restoring ability than pure
decitabine, zebularine and RG108.
Methods
Plasmids
The mammalianized nitroreductase gene B (TMnfsB) vector
was generated by subcloning the nitroreductase open
reading frame from existing constructs kindly provided by
Grohmann et al. [26] into the pDsRED-C1-monomer
vector at a XhoI/BamHI site. A retroviral plasmid
pLNCX2-RFP-TMnfsB expressing RFP-TMnfsB fusion
was generated by subcloning the RFP-TMnfsB coding
fragment from the existing construct pDsRED-TMnfsB
(SnaBI/BamHI) into the pLNCX2 vector (SnaBI/BglII). All
constructs were confirmed by sequencing using appropriate
primers (Additional file 1).
Cell culture
All human cell lines were purchased from the American
Type Culture Collection (ATCC) except the Phoenix retro-
virus producer cell line which was kindly provided by Prof.
Garry Nolan of Stanford University (United States). All cell
lines were grown in the ATCC recommended media.
Reagents
CB1954 (soluble to 2 mg/mL in aqueous solution),
decitabine (soluble to 50 mg/mL in aqueous solution),
2(1H)-pyrimidinone riboside (zebularine; soluble to
16 mg/mL in DMSO) and RG108 (soluble to 10 mg/mL
in DMSO) were purchased from Sigma. RG108 is known
to be an ineffective DNMT inhibitor [27] and was
used as a negative control. Vorinostat (10 mM) was
kindly supplied by Dr. Lisa Butler of The University
of Adelaide (South Australia). All drugs were dissolved in
DMSO except decitabine, which was prepared in water
for liposomal formulation. The synthetic lipids 1,2-
dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] sodium
salt (DOPG), 1,2 distearoyl-sn-glycero-3-phosphocholine
(DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[amino(polyethylene glycol)-2000] ammonium salt
(DSPE-PEG2000) and natural cholesterol lipid were
purchased from Avanti Polar Lipids.
Generation of stable cell line and clonal selection
Recombinant retrovirus encoding RFP-TMnfsB was
produced using the Phoenix packaging cell line transfected
with Lipofectamine 2000 (Invitrogen) according to the
recommended protocol. Stable cell lines expressing RFP-
TMnfsB were generated by G418 selection of MCF10A
cells transduced with retrovirus expressing RFP-TMnfsB
for approximately 2 months. G418-resistant MCF10A cells
were grown into colonies in 10 cm dishes and potential
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isolated by treating these colonies with 5 μM of CB1954
for 72 hours. Surviving colonies, which were potentially
epigenetically silenced, were isolated as CB1954-resistant
clones. The integrity of RFP-TMnfsB in CB1954-resistant
clones was determined by screening using RT-PCR.
Finally, colonies with silenced RFP-TMnfsB insert were
identified by assessing TMnfsB and RFP expression using
RT-PCR and flow cytometry, respectively, after treatment
with epigenetic drugs.
Real-time polymerase chain reaction (RT-PCR)
RNA and DNA from the cells were extracted using the
RNeasy plant mini kit (Qiagen) and the DNeasy Blood
and Tissue Kit (Qiagen), respectively. cDNA was generated
using random primers and 20 U of reverse transcriptase
(Promega). TXNIP, TMnfsB and RFP-TMnfsB expression
were determined by qRT-PCR using IQ™ SYBR green
supermix (Biorad) and primers listed in Additional file 1.
Cycling conditions were: 10 min at 95°C followed by 40 re-
peats of 95°C for 10 s, annealing at appropriate temperature
for 15 s and extension at 72°C for 10 s. β-actin expression
was used for normalization of target gene expression.
Western blotting
Western blot analysis of RFP-TMnfsB fusion protein
expressed in MCF10A cells was performed using a rabbit
polyclonal anti-RFP antibody (Invitrogen) or mouse
anti-β-actin antibody (Sigma-Aldrich), and a secondary
donkey anti-rabbit IgG-HRP (GE Healthcare) or a sheep
anti-mouse IgG-HRP (GE Healthcare) [28]. Total cellular
proteins were extracted as described previously [29] and
visualized by an Enhanced Chemiluminescence Detection
Kit (Amersham Biosciences).
Flow cytometry
The reactivation of silenced RFP-TMnfsB was determined
by flow cytometry. Cells were plated at 40% 24 hours prior
to treatment. The approximate doubling time of the cells
is 48 hours. Cells were treated with each drug (decitabine
1, 5, 10, 30 and 50 μM; zebularine 50, 100, 250 and
500 μM; RG108 10 and 100 μM; vorinostat 1 and 2 μM)
for 48 or 72 hours in triplicate. The red-fluorescence of
cells was analyzed at a log scale of geometric mean of
FL3-H using FACSCalibur flow cytometer (BD). Data were
processed using WinMDI v2.8 software.
Preparation of liposomal decitabine
Liposomal formulations were prepared according to the
method developed by Sunoqrot and colleagues with
minor modifications [30]. Briefly, 5 mg (32.5 mol%)
DOPG, 4.9 mg (32.1 mol%) DSPC, 1.8 mg (3.3 mol%)
DSPE-PEG2000 and 2.4 mg (32.1 mol%) cholesterol
were dissolved in 5 mL of chloroform. Thin lipid filmswere generated after removing the solvent in a rotary
evaporator for 2 hours at room temperature. Liposomes
were formed when thin lipid films (4 mM) were
hydrated in 5 mL of water or 0.88 mM decitabine
dissolved in water for 1 hour at room temperature and
stored at 4°C. The samples were extruded ten times using
200 and 400 nm polycarbonate membranes to obtain
unilamellar liposomes.
High performance liquid chromatography (HPLC)
HPLC (Shimadzu LC-10AT) analysis was done using a
XTerraTM C8 analytical column at 254 nm, using MiliQ
water as mobile phase and a flow rate of 0.8 mL/min. The
limit of quantification of decitabine is 10 ng/mL [31,32].
Liposomes characterization
The size and zeta potential of liposomes were characterized
by dynamic laser light scattering (Malvern Zetasizer
Nanoseries). Data are expressed as the mean plus standard
deviation of three technical repetitive measurements. For
determination of encapsulation efficiency, free decitabine in
the supernatant was collected after centrifugation at 82,508
xg for 30 minutes at 4°C and measured by HPLC. The
encapsulation efficacy of decitabine was defined as the mass
ratio between the amount of drugs incorporated in
liposomes and that used in the liposome preparation.
Controlled release study of liposomes formulated
decitabine
A controlled release study was performed using dialysis
tubing (regenerated cellulose tubing, Mw cut-off 12000,
43 mm flat width, Crown Scientific, Australia) incubated
in phosphate buffered saline (PBS) at 37°C. A 0.25 mL
decitabine liposome suspension was added to the dialysis
tubing immersed in a beaker with 10 mL of PBS as the
release medium. Aliquots of 0.1 mL were collected from
the solution outside the dialysis tubing at different time
points. The volume of PBS was maintained by addition of
0.1 mL PBS after each withdrawal. The concentration of
decitabine in each sample was determined using HPLC.
Statistical analysis
Data were analyzed by GraphPad Prism (GraphPad
Software, Inc.) using unpaired two-tailed t-tests, and
linear and nonlinear regression.
Results
Development of a cell-based assay system EPISSAY for
screening epigenetic drugs
The triple-mutated mammalianized version of nfsB,
TMnfsB [26], was selected for developing the assay system
as it showed the highest sensitivity to the lethal effect of
CB1954 (Additional file 2). The schematic of the develop-
ment of cell-based assay system for gene reactivation is in
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which expressed the cytomegalovirus (CMV) promoter
driven RFP-TMnfsB fusion protein (confirmed by western
blot analysis, data not shown).
The CMV promoter is known to be gradually silenced
over a period of months in culture and can be reactivated
by subsequent treatment with epigenetic drugs [23].
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Figure 1 The proposed EPISSAY system. (A) Schematic showing differen
efficiency of epigenetic drugs. (B) Chemical structure of the epigenetic druincreased expression of RFP-TMnfsB fusion protein
after treatment with DNMT inhibitors (decitabine and
zebularine) by western blot and flow cytometry analyses
(Figure 2A). We observed that this was not due to
auto-fluorescence of basal MCF10A cells (Figure 2B).
This confirmed that the increased of red-fluorescent
reading in clone T1 contained cells is due to the reactiva-
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Ratio (anti-RFP/β-actin)  1.0         4.4       4.0        4.8        1.5        1.9        3.8
Figure 2 Selection for EPISSAY system. Flow cytometric assessment and western blot of the parental (A) RFP-TMnfsB expressing clone T1 and
(B) untransduced MCF10A cells. The densitometry on western blots was quantified using ImageJ program. (C) Flow cytometric assessment of the
CB1954-resistant clones generated from T1. Top panel: low fluorescent clones LT1, LT2 and LT3. Bottom panel: high fluorescent clones HT1, HT2,
HT3 and HT4. Treatments were: decitabine 1, 10, 50 μM or zebularine 50, 100, 500 μM for 72 hours in triplicate in <1% v/v DMSO. Red-fluorescent
reading is the gated geometric mean value of FL3-H. Note the different y axis scales for each panel. Unpaired two-tailed t-test, data expressed as
mean ± SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
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assay system, cells of the T1 clone were treated with
CB1954 to kill RFP positive cells which were expressing
RFP-TMnfsB. Surviving clones will include those where
the CMV promoter was silenced. These were screened for
sensitivity to treatment with DNMT inhibitors (Figure 2C).
Despite differences in the base levels of red-fluorescence,
the red-fluorescent signals of all clones increased after
treatment with decitabine and zebularine with clone LT1
showed the highest sensitivity.
Proof of principle of the assay system
Three clones, LT1, LT3 and HT2, selected for additional
testing were treated with decitabine and/or vorinostat for
72 hours, with media changes every 24 hours to maintain
drug levels. An increased level of red-fluorescence was
observed after treatment in all three clones (Figure 3A).
Since the red-fluorescent signal should reflect expression of
the RFP-TMnfsB gene, levels of TMnfsB mRNA were quan-
tified in the treated cells (Figure 3B). There was a significantcorrelation between levels of red-fluorescence and TMnfsB
expression in the clones with low and high initial red-
fluorescence, LT3 and HT2, treated with decitabine and/or
vorinostat (p < 0.0001), confirming that the red-fluorescent
signal is directly related to the levels of TMnfsB message.
Among these clones, LT1 showed a lower red-fluorescent
background and reasonable sensitivity to treatment with
epigenetic drugs (Figures 2 and 3). To further validate these
findings, the reactivation of two independent endogenous
target genes was also assayed. The genes chosen were
TXNIP (thioredoxin interacting protein) and ANKRD11
(ankyrin repeat domain 11 protein), which were previously
shown to be reactivated after treatment with decitabine
and/or vorinostat [5,33,34]. The amount of TXNIP and
ANKRD11 in the LT1 cells was assessed after treatment
with decitabine and/or vorinostat. A linear relationship of
red-fluorescence and TXNIP mRNA expression (p < 0.05),
and ANKRD11 mRNA expression (p < 0.05), was observed
(Figure 3C and 3D). Taken together, our data clearly show


















































































































































































































































Figure 3 Proof of principle of the assay system. (A) Flow cytometric assessment of CB1954-resistant clone expressing RFP-TMnfsB. HT2, LT1,
and LT3 were treated with 1 μM decitabine and/or 1, 2 μM of vorinostat (SAHA) for 48 hours. The average red-fluorescence of the treated cells
(n = 3) were correlated with the mRNA expression of (B) TMnfsB of treated HT2 and LT3 (C) TXNIP and (D) ANKRD11 of treated LT1 cells
normalized to β-actin expression (n = 1). The red-fluorescent reading for TXNIP and ANKRD11 analysis was normalized to vehicle control. All
treatments contain <1% v/v of DMSO.
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ANKRD11 reactivation in the cells treated with epigenetic
drugs. We have named LT1 clone as EPISSAY and selected
it for screening the activity of epigenetic drugs. We used
EPISSAY to determine the effectiveness of a liposomal
formulation of decitabine and to compare the existing
epigenetic drugs.
Development of liposomal formulated decitabine
Decitabine is an unstable compound that undergoes
hydrolysis [32] and degradation by cytidine deaminase [35].
To improve the stability and bioavailability of decitabine,
we formulated decitabine loaded liposomes by thin-film hy-
dration as multilamellar liposomes with a broad size distri-
bution of 871 ± 69 nm (Table 1). A narrow size distribution
of decitabine-loaded liposomes was obtained by extruding
the suspension through 400 nm and 200 nm filters to
achieve a size of 138 ± 5 nm as unilamellar liposomes. The
polydispersity index (PDI) of these extruded liposomes
was less than 0.5 of the scale of 1 and liposomal formula-
tion achieved an encapsulation efficacy of 55.1 ± 3.4%
(0.15 μg decitabine/mg of lipid). The zeta potential of
decitabine-loaded liposomes before extrusion was similarto the empty liposomes. The zeta potential of decitabine-
loaded liposomes before extrusion -69.9 ± 2.8 increased to
-40.2 ± 4.3 mV after extrusion. Overall the physiochemical
data confirmed the decitabine-loaded liposomes are highly
dispersed and achieved a smaller size <150 nm after
extrusion. The potency of these newly formulated
decitabine-loaded liposomes was subsequently com-
pared with the free drug using the EPISSAY system.
Use of EPISSAY system to determine the potency of
liposomal formulated decitabine
To compare the potency of a panel of epigenetic drugs
and newly formulated decitabine, LT1 cells were treated
with these drugs for 72 hours, with or without a media
change with fresh drug every 24 hours. Continuous treat-
ment is often required as genes can be re-methylated after
the removal of decitabine [36]. With a media change, 2 μM
vorinostat and unilamellar decitabine-loaded liposomes at
30 μM were found to be more potent than pure decitabine
and zebularine (Figure 4A). Notably, we observed a linear
dose-dependent response in cells treated with unilamellar
decitabine-loaded liposomes from 5 to 30 μM. There is a
50% increase of potency of the unilamellar decitabine-
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In both with and without a media change, no significant
difference was observed between treatment with 2 μM
vorinostat alone and in the presence of 1 μM decitabine.
To investigate whether liposomal formulation protects
decitabine from degradation, LT1 cells were treated with
different concentrations of decitabine and liposomal
decitabine for 72 hours without a media change
(Figure 4B). A study of the drug release profile showed that
50% of decitabine was released from both unilamellar and
multilamellar liposomes at ~90 minutes (Additional file 3).
At 4 hours, the release of decitabine from unilamellar
liposomes was slower (65%) than multilamellar liposomes
(80%), confirming the better potency of unilamellar
decitabine observed in Figure 4.
The potency of multilamellar decitabine-loaded liposomes
and pure decitabine without media change were lower
than those with the media change (Figure 4A and B).
Nevertheless, the potency of unilamellar decitabine-loaded
liposomes (10 μM) was maintained. Although unilamellar
decitabine-loaded liposomes (30 μM) have the highest
potency without media change, this was slightly reduced
in comparison with replacing the drug every 24 hours.
Taken together, our data showed that the potency of
decitabine is improved when delivered as a unilamellar
liposomal formulation.
Discussion
EPISSAY, a cell-based assay system for screening of
epigenetic drugs was developed based on the human non-
malignant breast epithelial cell line MCF10A expressing the
well-characterized CMV promoter driving RFP fused with
a mammalianized version of the bacterial nitroreductase nfs
gene. The nfs gene has been used in gene-directed enzyme
prodrug therapy [37] since treatment of mammalian
cells expressing nfs with CB1954 results in its chemical
reduction to cytotoxic metabolites. Exposure of the
derivative MCF10A with CB1954 was used as a strategy for
the selection of cell lines with silenced nfs genes.
The EPISSAY was verified by treatment with the known
epigenetic drugs decitabine, zebularine or vorinostat;all of which resulted in increased red-fluorescence
due to reactivation of the CMV promoter. There was a
linear relationship between nfs expression and the red-
fluorescent signal confirming that levels of gene message
and translated protein are directly related. The response
was further confirmed by measuring expression levels of
known independent endogenous genes TXNIP [5] and
ANKRD11 [34].
EPISSAY could be a time-saving assay for screening
compounds with gene reactivating activity. Standard
methodologies used to assess epigenetic compounds are
based on quantitative real-time PCR and western blot
analysis of genes known to be silenced in a particular cell
line. For example, quantification of the re-expression of an
endogenous gene p16 in human T24 bladder carcinoma
cell line was previously used [38]. Such approaches are
time-consuming as they require cell collection for RNA
and protein extractions prior to analysis. Other cell-based
assay systems which use exogenous expression of genes
(e.g. Escherichia coli β-D-galactosidase gene with and
green fluorescent reporter) have previously been investi-
gated for their potential in screening epigenetic drugs by
using fluorescent microscopy and plate readers. However,
these other systems have limitations such as the non-
quantitative data obtained and/or additional sample
treatments required (e.g Paraformaldehyde fixing, the
addition fluorogenic compounds) prior to screening [18-20]
(Additional file 4). EPISSAY requires limited sample
preparation, may be formatted for multi-well plates, and
rapid results can be generated from RFP reading using
flow cytometry to obtain quantitative data.
Decitabine is a demethylating agent that is FDA ap-
proved as an anti-cancer agent [13]. Since decitabine is
degraded in vivo with a half-life of only 25 minutes, daily
treatments are required to maintain appropriate drug levels
both in vitro and in vivo [39]. To improve the stability and
bioavailability of decitabine, the drug was encapsulated in
PEGylated liposomes, as liposomes are known to protect
drugs from degradation and allow controlled release of
drug into the environment [40]. This formulation achieved
an encapsulation efficiency of ~50%. Only 3.3 mol% of PEG
2000 was used in this study as a higher PEG content is
known to reduce adsorption of liposomes onto cells [41].
Liposomes were extruded through filters with defined
pore size (200 nm and 400 nm) to obtain unilamellar
liposomes. Although extrusion does not affect the
encapsulation efficiency [42], it narrowed the size distri-
bution of the liposomes from 1 μm to approximately
150 nm. The smaller size of the drug-loaded liposomes
has been reported to passively targeting disease tissues
due to their enhanced angiogenesis [43].
We used the EPISSAY system to determine if liposomal
encapsulation enhanced the gene reactivating activity of
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Figure 4 (See legend on next page.)
Lim et al. BMC Cancer 2013, 13:113 Page 8 of 11
http://www.biomedcentral.com/1471-2407/13/113
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Figure 4 The comparison of pure and newly-formulated epigenetic drugs using EPISSAY. Flow cytometric assessment of LT1 cells treated
with epigenetic drugs. Treatments were: liposomal formulated or pure decitabine 1, 5, 10, 30 μM and/or pure vorinostat 1, 2 μM; pure zebularine
250, 500 μM; pure RG108 10, 100 μM (A) with or (B) without media change for 72 hours in triplicate. The gated geometric mean values of FL3-H
(red-fluorescence) were normalized to the vehicle control, drug-free liposomes and water. Lipo: multilamellar decitabine-loaded liposomes; E-lipo:
unilamellar decitabine-loaded liposomes. Pure: drug without modification. Unpaired two-tailed t-test, data expressed as mean ± SEM. * = p < 0.05,
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
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potency than pure decitabine, suggesting that decitabine
was protected in the liposomes and slowly released into
the media. These results were supported by a controlled
release study comparing the drug release of decitabine
from unilamellar and multilamellar liposomes. This showed
that the release rate of decitabine from unilamellar
liposomes was slower, suggesting unilamellar liposomal
formulation may decrease the rate of degradation of
decitabine by providing protection to the drug. In
addition, the liposomal formulation and the presence of
phospholipids in the cell media could also contribute to
the enhancement of decitabine activity [44,45].
Collectively, the liposomal decitabine that was synthesised
here was validated as a more potent epigenetic drug.
However, we have only confirmed this in vitro. An
in vivo study of liposomal decitabine is recommended
to assess its applicability for clinical use, and to confirm if
the present limitations of decitabine use in the clinic could
be overcome by this formulation. The use of liposomes/
PEG to encapsulate drugs to improve their bio-availability
and stability is now gaining momentum with a number of
drugs eg doxorubicin [17], rhenium radionuclides [46] and
dexamethasone phosphate [47], liposome-encapsulated
doxorubicin now having FDA approval.
Conclusions
In this pilot study, we have constructed and evaluated a
novel bioassay for epigenetic compounds. The readout
of the EPISSAY system is red-fluorescence, which may
allow the adaptation of the assay system to a multi-well
format allowing high throughput, rapid, and cheap
bioassay in the future. EPISSAY was successful in providing
evaluation of different liposomal formulations of decitabine.
The EPISSAY can detect the gene reactivating effects of
decitabine, zebularine or vorinostat. Linear correlation
between the message of an endogenous gene ANKRD11
and red-fluorescent reading has been shown in the
EPISSAY cells treated with pure decitabine and unilamellar
liposomes-formulated decitabine (Additional file 5).
Using SEQUENOM MassARRAY EpiTYPER, no major
changes in methylation of the CMV promoter was detected
in the EPISSAY cells before and after treatments with
decitabine (Additional file 6 and 7). Although vorinostat is
known as a HDAC inhibitor to activate gene expression,
zebularine and decitabine are usually considered tofunction as demethylating agents or DNMT inhibitors [48].
However, there are now multiple studies that show these
agents can also function as HDAC inhibitors [49-51]. This
suggests that the TMnfsB gene was most likely silenced by
histone modification rather than direct methylation of the
CMV promoter. There is a potential of adopting this assay
as a high throughput, rapid and low cost epigenetic drug
screening platform are unique aspects of the EPISSAY
system. We conclude that our EPISSAY bioassay system
provides a novel and rapid system to screen the effi-
ciencies of epigenetic and newly formulated drugs for
gene reactivation.Additional files
Additional file 1: PCR primers used in this study.
Additional file 2: Sensitivity of different nitroreductase genes to
CB1954. Transiently transfected HEK293T cells with (A) pDsRED-
monomer-C1 vector, (B) pDsRED-nfsA, (C) pDsRED-nfsB, (D) pDsRED-
MnfsB, (E) pDsRED-TMnfsB and incubated with 0, 1, 5, 10 μM of CB1954
for 24 hours at 37°C/ 5% CO2. All contain 0.2% v/v DMSO. The decreased
of red-fluorescence indicates cell death.
Additional file 3: Controlled release study of liposomal decitabine.
(A) The standard plot of pure decitabine produced using HPLC at 254
nm (retention time = 6.554 ± 0.003 minutes). (B) Drug release profiles of
unilamellar and multilamellar liposomal decitabine at different time
intervals generated using the standard plot of pure decitabine.
Additional file 4: Characteristics of previously investigated
epigenetic cell-based assay systems.
Additional file 5: The correlation of endogenous ANKRD11
expression and the relative red-fluorescence in the EPISSAY system.
The average red-fluorescence of the treated cells (n=3) were correlated
with the mRNA expression of ANKRD11 (n=1). The EPISSAY (LT1) cells
were treated with 1, 5, 10, 30 μM of pure decitabine and unilamellar
liposomes-formulated decitabine for 72 hours with/ without a media
change every 24 hours to replenish the level of drugs. ANKRD11 of
treated LT1 cells was normalized to β-actin expression. The red-
fluorescent reading was normalized to vehicle control.
Additional file 6: Epigram showing methylation levels of the CMV
promoter generated from SEQUENOM EpiTYPER Platform. This
epigram showed % CpG methylation of CMV promoter in overlapping
regions of CMV_1 and CMV_2 amplicons of RFP-TMnfsB expressing
clones treated with epigenetic drugs are indicated (n=2). Dec: decitabine;
Zeb: zebularine. LT1 is the CB1954-resistant clone, which subsequently in
used as the basis of EPISSAY. T1 is the parental clone without CB1954
selection and has a higher red-fluorescent background than LT1. The
CpG units are as defined in Addition file 7.
Additional file 7: Amplicon design and the target region for
methylation analysis. Bisulfite treated sequence of CMV promoter
regions: CMV_1; CMV_2. [T bold: cytosine from non-CG converted to T;
italic smaller font: primer target sequence; all CGs: bold; CG underlined:
analysed CGs; |Unit|: fragment with different mass and size generated by
enzymatic base specific cleavage].
Lim et al. BMC Cancer 2013, 13:113 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/113Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SPL carried out all the experimental work and drafted the manuscript. RK
carried out the molecular biology studies, participated in the experimental
design and contributed to drafting and editing of the manuscript. YA and
WW participated in the study of nanotechnology. KH, PMN and DJW
contributed to the molecular biology studies. RJS was involved in the design
of the study, performed the statistical analysis and edited the manuscript. CP
reviewed the study and participated in the nanotechnology work. DFC
supervised the study, and contributed to its design and coordination and
helped to draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors have no conflict of interest directly related to the content of this
paper.
Author details
1Cancer Therapeutics Laboratory, Centre for Personalized Cancer Medicine,
The University of Adelaide, Adelaide, South Australia, Australia. 2Women’s &
Children’s Health Research Institute Inc, North Adelaide, South Australia,
Australia. 3Ian Wark Research Institute, University of South Australia, Mawson
Lakes Boulevard, Mawson Lakes, South Australia, Australia. 4Max Planck
Institute for Molecular Genetics, Berlin, Germany.
Received: 8 October 2012 Accepted: 5 March 2013
Published: 13 March 2013
References
1. Richards EJ, Elgin SCR: Epigenetic Codes for Heterochromatin Formation
and Silencing: Rounding up the Usual Suspects. Cell 2002, 108:489–500.
2. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP:
Histone deacetylases (HDACs): characterization of the classical HDAC
family. Biochem J 2003, 370:737–749.
3. Burgers WA, Fuks F, Kouzarides T: DNA methyltransferases get connected
to chromatin. Trends Genet 2002, 18:275–277.
4. Ballestar E, Esteller M: The impact of chromatin in human cancer: linking
DNA methylation to gene silencing. Carcinogenesis 2002, 23:1103–1109.
5. Butler LM, Zhou X, Xu W-S, Scher HI, Rifkind RA, Marks PA, Richon VM: The
histone deacetylase inhibitor SAHA arrests cancer cell growth,
up-regulates thioredoxin-binding protein-2, and down-regulates
thioredoxin. Proc Natl Acad Sci 2002, 99:11700–11705.
6. Lyko F, Brown R: DNA Methyltransferase Inhibitors and the Development
of Epigenetic Cancer Therapies. J Natl Canc Inst 2005, 97:1498–1506.
7. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman
JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel
class of HDAC inhibitors inducing differentiation of transformed cells.
EMBO J 2001, 20:6969–6978.
8. Singh TR, Shankar S, Srivastava RK: HDAC inhibitors enhance the
apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene
2005, 24:4609–4623.
9. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract
2005, 2:4–11.
10. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek
V, Slack J, de Castro C, Ravandi F, et al: Decitabine improves patient
outcomes in myelodysplastic syndromes. Cancer 2006, 106:1794–1803.
11. Santini V, Gozzini A, Ferrari G: Histone Deacetylase Inhibitors: Molecular
and Biological Activity as a Premise to Clinical Application. Curr Drug
Metab 2007, 8:383–394.
12. Kirschbaum M, Gojo I, Goldberg SL, Kujawski L, Atallah E, Marks P, Gravio
DD, Pyle L, Rizvi S, Issa J-PJ: Vorinostat in Combination with Decitabine for
the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous
Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I,
Dose-Escalation Study. ASH Annual Meeting Abstracts 2089, 2009:114.
13. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase
inhibitors azacytidine and decitabine. Int J Cancer 2008, 123:8–13.
14. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L,
Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR: Evaluation of a
7-Day Continuous Intravenous Infusion of Decitabine: Inhibition ofPromoter-Specific and Global Genomic DNA Methylation. J Clin Oncol
2005, 23:3897–3905.
15. Issa JJ, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderi S, Bayar E,
Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase I study of low-dose
prolonged exposure schedules of the hypomethylating agent 5-aza-20-
deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004,
103:1635–1640.
16. Smith AM, Jaime-Fonseca MR, Grover LM, Bakalis S: Alginate-Loaded
Liposomes Can Protect Encapsulated Alkaline Phosphatase Functionality
When Exposed to Gastric pH. J Agric Food Chem 2010, 58:4719–4724.
17. Rose PG: Pegylated Liposomal Doxorubicin: Optimizing the Dosing
Schedule in Ovarian Cancer. Oncologist 2005, 10:205–214.
18. Byun H-M, Choi SH, Laird PW, Trinh B, Siddiqui MA, Marquez VE, Yang AS:
20-Deoxy-N4-[2-(4-nitrophenyl) ethoxycarbonyl]-5-azacytidine: a novel
inhibitor of DNA methyltransferase that requires activation by human
carboxylesterase 1. Cancer Lett 2008, 266:238–248.
19. Villar-Garea A, Fraga MF, Espada J, Esteller M: Procaine Is a DNA-demethylating
Agent with Growth-inhibitory Effects in Human Cancer Cells. Cancer Res 2003,
63:4984–4989.
20. Biard DSF, Cordier A, Sarasin A: Establishment of a human cell line for the
detection of demethylating agents. Exp Cell Res 1992, 200:263–271.
21. Okochi-Takada E, Ichimura S, Kaneda A, Sugimura T, Ushijima T:
Establishment of a detection system for demethylating agents using an
endogenous promoter CpG island. Mutat Res Fundam Mol Mech Mutagen
2004, 568:187–194.
22. Hassig CA, Symons KT, Guo X, Nguyen P-M, Annable T, Wash PL, Payne JE,
Jenkins DA, Bonnefous C, Trotter C, et al: KD5170, a novel mercaptoketone-
based histone deacetylase inhibitor that exhibits broad spectrum
antitumor activity in vitro and in vivo. Mol Cancer Ther 2008, 7:1054–1065.
23. Choi K, Basma H, Singh J, Cheng P-W: Activation of CMV promoter-controlled
glycosyltransferase and β -galactosidase glycogenes by butyrate, tricostatin
A, and 5-Aza-20-deoxycytidine. Glycoconj J 2005, 22:63–69.
24. Kong Q, Wu M, Huan Y, Zhang L, Liu H, Bou G, Luo Y, Mu Y, Liu Z:
Transgene Expression Is Associated with Copy Number and
Cytomegalovirus Promoter Methylation in Transgenic Pigs. PLoS One
2009, 4:e6679.
25. Denny WA: Nitroreductase-based GDEPT. Curr Pharm Des 2002, 8:1349–1361.
26. Grohmann M, Paulmann N, Fleischhauer S, Vowinckel J, Priller J, Walther D:
A mammalianized synthetic nitroreductase gene for high-level
expression. BMC Canc 2009, 9:301.
27. Lim SP, Neilsen P, Kumar R, Abell A, Callen DF: The application of delivery
systems for DNA methyltransferase inhibitors. BioDrugs 2011, 25:227–242.
28. Kumar R, Cheney KM, McKirdy R, Neilsen PM, Schulz RB, Lee J, Cohen J,
Booker GW, Callen DF: CBFA2T3-ZNF652 Corepressor Complex Regulates
Transcription of the E-box Gene HEB. J Biol Chem 2008,
283:19026–19038.
29. Kumar R, Manning J, Spendlove HE, Kremmidiotis G, McKirdy R, Lee J,
Millband DN, Cheney KM, Stampfer MR, Dwivedi PP, et al: ZNF652, A Novel
Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor
CBFA2T3 to Repress Transcription. Mol Canc Res 2006, 4:655–665.
30. Sunoqrot S, Bae JW, Jin S-E M, Pearson R, Liu Y, Hong S: Kinetically
Controlled Cellular Interactions of Polymer-Polymer and Polymer-
Liposome Nanohybrid Systems. Bioconjug Chem 2011, 22:466–474.
31. Patel K, Guichard SM, Jodrell DI: Simultaneous determination of
decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by
liquid chromatography tandem mass spectrometry for clinical studies.
J Chromatogr B 2008, 863:19–25.
32. Lin K-T, Momparlerm RL, Rivard GE: High-performance liquid
chromatographic analysis of chemical stability of 5-aza-20-deoxycytidine.
J Pharm Sci 1981, 70:1228–1232.
33. Ahsan MK, Masutani H, Yamaguchi Y, Kim YC, Nosaka K, Matsuoka M,
Nishinaka Y, Maeda M, Yodoi J: Loss of interleukin-2-dependency in HTLV-
I-infected T cells on gene silencing of thioredoxin-binding protein-2.
Oncogene 2006, 25:2181–2191.
34. Lim SP, Wong NC, Suetani RJ, Ho K, Ng JL, Neilsen PM, Gill PG, Kumar R,
Callen DF: Specific-site methylation of tumour suppressor ANKRD11 in
breast cancer. Eur J Cancer 2012, 48:3300–3309.
35. Chabot GG, Bouchard J, Momparler RL: Kinetics of deamination of 5-aza-20-
deoxycytidine and cytosine arabinoside by human liver cytidine deaminase
and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Biochem Pharmacol 1983, 32:1327–1328.
Lim et al. BMC Cancer 2013, 13:113 Page 11 of 11
http://www.biomedcentral.com/1471-2407/13/11336. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa J-PJ:
Chromatin remodeling is required for gene reactivation after Decitabine-
mediated DNA hypomethylation. Cancer Res 2010, 70:6968–6977.
37. Mitchell DJ, Minchin RF: E. coli nitroreductase/CB1954 gene-directed
enzyme prodrug therapy: role of arylamine N-acetlytransferase 2. Canc
Gene Ther 2008, 15:758–764.
38. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA,
Selker EU: Inhibition of DNA Methylation and Reactivation of Silenced
Genes by Zebularine. J Natl Canc Inst 2003, 95:399–409.
39. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel
L, Aukerman SL, Heise C, MacBeth KJ: A Comparison of Azacitidine and
Decitabine Activities in Acute Myeloid Leukemia Cell Lines. PLoS One
2010, 5:e9001.
40. Immordino ML, Dosio F, Cattel L: Stealth liposomes: review of the basic
science, rationale, and clinical applications, existing and potential.
Int J Nanomedicine 2006, 1:297–315.
41. Er Y, Barnes TJ, Fornasiero D, Prestidge CA: The encapsulation and release
of guanosine from PEGylated liposomes. J Liposome Res 2009, 19:29–36.
42. Colletier J-P, Chaize B, Winterhalter M, Fournier D: Protein encapsulation in
liposomes: efficiency depends on interactions between protein and
phospholipid bilayer. BMC Biotechnol 2002, 2:9.
43. Maruyama K, Ishida O, Takizawa T, Moribe K: Possibility of active targeting
to tumor tissues with liposomes. Adv Drug Deliv Rev 1999, 40:89–102.
44. McAllister SM, Alpar HO, Brown MR: Antimicrobial properties of liposomal
polymyxin B. J Antimicrob Chemother 1999, 43:203–210.
45. Egbaria K, Weiner N: Liposomes as a topical drug delivery system. Adv
Drug Deliv Rev 1990, 5:287–300.
46. Hrycushko BA, Li S, Goins B, Otto RA, Bao A: Direct intratumoral infusion of
liposome encapsulated rhenium radionuclides for cancer therapy: effects
of nonuniform intratumoral dose distribution. Med Phys 2011, 38:1339–1347.
47. Anderson R, Franch A, Castell M, Perez-Cano FJ, Brauer R, Pohlers D, Gajda
M, Siskos AP, Katsila T, Tamvakopoulos C, et al: Liposomal encapsulation
enhances and prolongs the anti-inflammatory effects of water-soluble
dexamethasone phosphate in experimental adjuvant arthritis. Arthritis
Res Ther 2010, 12:R147.
48. Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Oncology: In Small
Molecules in; 2010:131–157.
49. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan
S, Narayan D, Bacchiocchi A, Molinaro A, et al: Integrative Analysis of
Epigenetic Modulation in Melanoma Cell Response to Decitabine:
Clinical Implications. PLoS One 2009, 4:e4563.
50. Scott SA, Dong W-F, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE,
Geyer CR, DeCoteau JF: 5-Aza-20-deoxycytidine (decitabine) can relieve
p21WAF1 repression in human acute myeloid leukemia by a mechanism
involving release of histone deacetylase 1 (HDAC1) without requiring
p21WAF1 promoter demethylation. Leuk Res 2006, 30:69–76.
51. Lavelle D, Vaitkus K, Hankewych M, Singh M, DeSimone J: Effect of 5-aza
-20-deoxycytidine (Dacogen) on covalent histone modifications of
chromatin associated with the ε-, γ-, and β-globin promoters in Papio
anubis. Exp Hematol 2006, 34:339–347.
doi:10.1186/1471-2407-13-113
Cite this article as: Lim et al.: Development of a novel cell-based assay
system EPISSAY for screening epigenetic drugs and liposome
formulated decitabine. BMC Cancer 2013 13:113.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
